Attovia Therapeutics ATTO
Attovia Therapeutics, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)
$15.80+5.33%close on Oct. 28, 2026 · volume 175K · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 6, 2026 | Colin Walsh director · indirect | Bought amended | 500,000 | $17.00 | $8.50 million |
| Aug. 6, 2026 | Goldman Sachs Group Inc with Goldman Sachs & Co. LLC, Goldman Sachs Asset Management L.P., Broad Street Principal Investments L.L.C., Wsls Offshore Investments SLP, West Street Life Sciences I L.P., Wsls EMP Offshore Investments L.P., Wsls EMP Onshore Investments L.P. reporting person · indirect | Bought amended | 500,000 | $17.00 | $8.50 million |
| Aug. 6, 2026 | venBio Global Strategic Fund IV L.P. 10% owner | Bought | 382,352 | $17.00 | $6.50 million |
| Aug. 6, 2026 | Redmile Group LLC with Jeremy Green, Redmile Biopharma Investments III L.P. 10% owner | Bought | 200,000 | $17.00 | $3.40 million |
| Aug. 6, 2026 | Redmile Group LLC with Jeremy Green, Redmile Biopharma Investments III L.P. 10% owner · indirect | Bought | 400,000 | $17.00 | $6.80 million |
| Aug. 6, 2026 | Sanofi 10% owner · indirect | Bought | 300,000 | $17.00 | $5.10 million |
| Aug. 6, 2026 | Frazier Life Sciences XI L.P. with Fhmls XI L.P., Xi L.l.c. Fhmls 10% owner | Bought | 588,235 | $17.00 | $10.00 million |
| Aug. 5, 2026 | Colin Walsh director · indirect | Bought amended | 85,000 | $21.00 | $1.78 million |
| Aug. 5, 2026 | Colin Walsh director · indirect | Sold amended | 105,807 | $21.28 $20.84-$22.19 | $2.25 million |
| Aug. 5, 2026 | Goldman Sachs Group Inc with Goldman Sachs & Co. LLC, Goldman Sachs Asset Management L.P., Broad Street Principal Investments L.L.C., Wsls Offshore Investments SLP, West Street Life Sciences I L.P., Wsls EMP Offshore Investments L.P., Wsls EMP Onshore Investments L.P. reporting person · indirect | Bought amended | 85,000 | $21.00 | $1.78 million |
| Aug. 5, 2026 | Goldman Sachs Group Inc with Goldman Sachs & Co. LLC, Goldman Sachs Asset Management L.P., Broad Street Principal Investments L.L.C., Wsls Offshore Investments SLP, West Street Life Sciences I L.P., Wsls EMP Offshore Investments L.P., Wsls EMP Onshore Investments L.P. reporting person · indirect | Sold amended | 105,807 | $21.28 $20.84-$22.19 | $2.25 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 26 →Results of operations and financial condition · Financial statements and exhibits